SCHEMBL20813451

SCHEMBL20813451

Ic1ncnc2cc3c(cc12)OCO3

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.48
EGFR P00533 11/20 0.46
ABL1 P00519 3/20 0.45
PDGFRB P09619 3/20 0.45
FGFR1 P11362 3/20 0.45
SRC P12931 3/20 0.45
KDR P35968 2/20 0.45
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 3/20 0.39
CYP2C19 P33261 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
HIF1A Q16665 1/20 0.39
MPO P05164 2/20 0.37
PI4K2A Q9BTU6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16447456 0.78 ALDH1A1 (0.49) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL29589537 0.78 PDE5A (0.48) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL8807079 0.78 PDE5A (0.48) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL367950 0.78 PDE5A (0.48) PDE5AEGFRABL1PDGFRBFGFR1
Hydrochloric Acid SCHEMBL8808443 0.76 PDE5A (0.47) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL24391688 0.74 PDE5A (0.45) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL3520125 0.71 CLK4 (0.62) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL11852402 0.69 PDE5A (0.64) PDE5AEGFRABL1PDGFRBFGFR1
SCHEMBL2913230 0.68 CYP1A2 (0.71) PDGFRBCYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL20813468 0.68 EGFR (0.41) EGFRSRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4327882-A2 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER The Board of Trustees of the Leland Stanford Junior University (US) 2024-02-28 EP disclosed
WO-2023077083-A1 ENPP1 INHIBITORS AS INHIBITORS OF METASTASIS ANGARUS THERAPEUTICS, INC. (US) 2023-05-04 WO disclosed
WO-2021226136-A1 ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE ANGARUS THERAPEUTICS, INC. (US) 2021-11-11 WO disclosed
WO-2019051269-A1 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2019-03-14 WO disclosed